Format

Send to

Choose Destination
Yonsei Med J. 2016 Jul;57(4):831-9. doi: 10.3349/ymj.2016.57.4.831.

Fibroblast Growth Factor Receptor 1 Overexpression Is Associated with Poor Survival in Patients with Resected Muscle Invasive Urothelial Carcinoma.

Lim S1,2, Koh MJ3, Jeong HJ4, Cho NH2,4, Choi YD2,5,6, Cho do Y7, Lee HY8, Rha SY2,6,9,10.

Author information

1
Department of Internal Medicine, Wonju Severance Christian Hospital, Wonju, Korea.
2
Department of Medicine, Graduate School of Yonsei University College of Medicine, Seoul, Korea.
3
Department of Pathology, Daedong Hospital, Busan, Korea.
4
Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.
5
Department of Urology, Yonsei University College of Medicine, Seoul, Korea.
6
Yonsei Cancer Center, Yonsei University Health System, Seoul, Korea.
7
Department of Hematology and Oncology, Konyang University College of Medicine, Daejeon, Korea.
8
Department of Pharmacology, Myunggok Medical Research Institute, College of Medicine, Konyang University, Daejeon, Korea.
9
Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
10
Song-Dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Korea. rha7655@yuhs.ac.

Abstract

PURPOSE:

To examine the usefulness of various receptor tyrosine kinase expressions as prognostic markers and therapeutic targets in muscle invasive urothelial cancer (UC) patients.

MATERIALS AND METHODS:

We retrospectively analyzed the data of 98 patients with muscle invasive UC who underwent radical cystectomy between 2005 and 2010 in Yonsei Cancer Center. Using formalin fixed paraffin embedded tissues of primary tumors, immunohistochemical staining was done for human epidermal growth factor receptor 2 (HER2), fibroblast growth factor receptor 1 (FGFR1), and fibroblast growth factor receptor 3 (FGFR3).

RESULTS:

There were 41 (41.8%), 44 (44.9%), and 14 (14.2%) patients who have over-expressed HER2, FGFR1, and FGFR3, respectively. In univariate analysis, significantly shorter median time to recurrence (TTR) (12.9 months vs. 49.0 months; p=0.008) and overall survival (OS) (22.3 months vs. 52.7 months; p=0.006) was found in patients with FGFR1 overexpression. By contrast, there was no difference in TTR or OS according to the HER2 and FGFR3 expression status. FGFR1 remained as a significant prognostic factor for OS with hazard ratio of 2.23 (95% confidence interval: 1.27-3.90, p=0.006) in multivariate analysis.

CONCLUSION:

Our result showed that FGFR1 expression, but not FGFR3, is an adverse prognostic factor in muscle invasive UC patients after radical cystectomy. FGFR1 might be feasible for prognosis prediction and a potential therapeutic target after thorough validation in muscle invasive UC.

KEYWORDS:

Urinary bladder neoplasms; cystectomy; prognosis; receptor tyrosine kinases

PMID:
27189274
PMCID:
PMC4951457
DOI:
10.3349/ymj.2016.57.4.831
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Yonsei University College of Medicine Icon for PubMed Central
Loading ...
Support Center